Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients

• Published in: International journal of antimicrobial agents Vol. 48; no. 3; pp. 259 - 264
• Main Authors: Dong, Haiyan, Xie, Jiao, Wang, Taotao, Chen, Lihong, Zeng, Xiaoyan, Sun, Jinyao, Wang, Xue, Dong, Yalin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.09.2016
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - pharmacokinetics; Anti-Bacterial Agents - pharmacology; Critical Illness; Critically ill patients; Drug Monitoring; Female; Humans; Infectious Disease; Linezolid; Linezolid - administration & dosage; Linezolid - pharmacokinetics; Linezolid - pharmacology; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Retrospective Studies; Staphylococcal infection; Staphylococcal Infections - drug therapy; Staphylococcus - drug effects; Time Factors; Treatment Outcome; Young Adult; Linezolid; Staphylococcal infection; Critically ill patients
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2016.05.009

Highlights • Factors influencing the efficacy of linezolid treatment were analysed. • The target for successful treatment in critically staphylococcal infectious patients was determined based on PK/PD. • The target of AUC24 /MIC (120.5) was required to achieve 80% staphylococcal eradication. • The PTA for successful treatment was not achieved with the standard dosing regimen (600 mg every 12 h) at MIC > 1 mg/L. • For staphylococci, high doses may be needed to improve outcomes at MIC > 1 mg/L in critically ill patients.